• Family of patient who died after orthopedic surgery wins $35M verdict against hospital
  • Orthopedic surgeon wins $20M verdict against Johnson & Johnson
  • Minnesota orthopedic group hit with $111M negligence verdict
  • Orthopedic patient's death highlights potential dangers of prior authorization
  • Spine surgeon's video hits 1 million views on TikTok
  • Spine surgeon killed in Oklahoma hospital shooting
  • Spine surgeon owes $17M to paralyzed patient
  • Providence to pay $22.7M to settle unnecessary spine surgery allegations
  • Spine surgeon gets jail time for abusing patient during hospital visit
  • 'They're on really thin ice': Why 1 insurer has drawn spine surgeons' ire
  • Connecticut hospital to appeal $12.5M verdict to family of patient who died after orthopedic surgery
  • Orthopedic surgeon must face suit in patient's death
  • 23 spine device companies to watch in 2022
  • Spine surgeon 1 of 9 physician billionaires on Forbes' 2022 list
  • 4 spine technologies that promised more than they delivered
  • Orthopedic surgeon salary vs. average household income in each state
  • Orthopedic surgeon's health system exit steeped in controversy
  • Terminated orthopedic surgeon contracts with another New York hospital
  • Billionaire spine surgeon buys $23.9M mansion
  • Orthopedic surgeon convicted of battery at hospital
  • Texas spine surgeon defending himself from 'Dr. Death 2.0' allegations
  • UArizona neurosurgery chair dies after motorcycle collision
  • Texas spine surgeon sued by State Farm over 'unnecessary' procedures
  • The spine tech surgeons say will explode in the next 5 years
  • Could Medtronic's spine business be the next medtech spinoff?
  • 41 'rising stars' in orthopedics
  • Orthopedic surgeon indicted in $10M telemedicine fraud scheme
  • Neurosurgeon's startup hits $1.2B valuation
  • Orthopedic surgeon fined for operating on wrong knee
  • Lawsuits build against Aetna's spine surgery coverage
  • Good news, bad news for orthopedic surgeons: 6 observations
  • Walmart's latest partnership pushes retailer into spine care
  • Texas spine surgeon's $11M verdict being appealed
  • 10 power players in orthopedics
  • Rothman Orthopaedics to become national brand, but no 'aspirations to go beyond US'
  • Sports medicine physician fired amid misconduct allegations involving patients
  • Florida hospital patients say they were injured during surgeries. Now a physician faces 350 lawsuits.
  • Top orthopedic hospital in every state: US News
  • Orthopedic surgeon allegedly exaggerated patient visits to defraud insurers
  • Orthopedic surgeon asking for misconduct charges to be dropped
  • Tennessee's largest orthopedic group opens 2nd new location in a month
  • 3 New Jersey orthopedic groups merge, form OrthoEast
  • HSS surgeons react to 13th top orthopedic hospital ranking by US News
  • United Musculoskeletal Partners merges with Novum Orthopedic Partners
  • Private equity creeps further into orthopedics: 15 practice partnerships in 2022
  • Solving the issue of 'too much data': HOPCo's cross-continent partnership to create world's largest MSK database

    Solving the issue of 'too much data': HOPCo's cross-continent partnership to create world's largest MSK database

    Alan Condon -  

    Phoenix-based Healthcare Outcomes Performance Company has acquired two applications from London-based Future Health Works and set its sights on creating the world's largest integrated musculoskeletal data platform.

    David Jacofsky, MD, chair and CEO of HOPCo, and Dr. Thomas Harte, CEO and co-founder of FHW, spoke to Becker's about how the artificial intelligence-based applications can simplify the transition to value-based care and accelerate the ability to connect patients, providers and payers. 

    Question: Specifically, in terms of evidence-based protocols and value-based care, how will HOPCo and its partners benefit from FHW's technology?

    Dr. David Jacofsky: For those participating in [Bundled Payments for Care Improvement Advanced] or value-based care programs, complications and readmissions are two of the largest cost drivers. The msk.ai and myrecovery applications utilize state-of-the-art artificial intelligence, motion capture, real-time patient feedback, remote patient monitoring and predictive analytics technologies to track and report outcomes. The data captured through the platform can identify patients at risk of complications or hospital readmissions and allow the physician or provider to intervene before this occurs.  

    In more robust programs, such as population health risk models or condition-based bundles, this technology allows for multinodal algorithms within the patient management structure. For example, the instructions, recommendations, therapy or tracking questions that are pushed out to a patient will be updated in real time based on the performance and condition of the patient and the predictive analytics in the background, making it easy for providers or nurse navigators to approve.

    When we couple this with HOPCo's existing claims analytics, hospital and clinical datasets, and outcomes data, we can increase physician, payer and patient engagement in value-based programs and drive improved outcomes and savings across the country. We also aim to continue to grow the use of these broader data sets for evidence-based decision making.

    Q: What made FHW stand out from other U.S.-based companies in the same market?

    DJ: The biggest differentiator was the FHW team had built technologies to encompass the entire spectrum of musculoskeletal care. There are companies with applications that can measure knee replacement outcomes or spine procedure outcomes, and they do that well. Some manage remote therapy very well. A few can help with care navigation or with patient-reported outcomes.  

    However, many of our at-risk programs across the country cover over 26,000 ICD-10 codes related to musculoskeletal care. So, having a technology that was only applicable for select procedures or small slivers of the continuum was not what we needed. We wanted a comprehensive solution that was user-friendly and engaging that we could utilize across the country, and that is what the FHW team had developed. Additionally, the physician and patient engagement rates with their tools exceeded those we had seen in other platforms.

    Q: How can FHW's success in the U.K. translate to the U.S. healthcare system?

    Dr. Thomas Harte: Although much of the payer models may differ from the U.S., the imperatives remain the same. Both the U.K. and U.S. health systems have increasingly put pressure on physicians to improve outcomes and reduce costs. Therefore, the tools and analytics developed in the U.K. have the same application in the U.S. because they drive toward the same goal of pathway optimization and improved patient satisfaction. 

    Q: How will the HOPCo-FHW partnership develop in the future? What are the next steps in the integration process?

    TH: Our immediate plans are to utilize the investment from HOPCo to further accelerate our growth and significantly grow our team. London has become an epicenter for technology and AI and we have access to some of the best and brightest developers and programmers. We plan to continue to grow the platform's capabilities while utilizing HOPCo's subject matter expertise to help replicate the success we have had in the U.K. here in the U.S.

    Q: What does HOPCo aim to achieve in the musculoskeletal data management space in the next five years? 

    DJ: One of the biggest challenges we are trying to solve may seem counterintuitive, but it is the problem of too much data. The vast majority of data presented to providers today is fraught with inaccuracies and a lack of the standard definitions or data governance rules that anyone in other industries would consider acceptable practice. Data volume is important, but high-value and actionable data that is in near real time will ultimately win the day and drive change.  

    In the U.S. specifically, we suffer from data that is often difficult to access and commonly lives in disparate systems that do not integrate easily. Many providers work within three or four different EMRs in a given week, and this doesn't even get into the various claims processing, operational and financial systems utilized today in healthcare. So, the problem is not a lack of data but rather a lack of ability to present it in a meaningful way, coupled with a lack of standardized benchmarks to add actionable meaning to the data points.

    Our goal is to leverage FHW technologies and incorporate our own claims analytics, benchmarks, standard definitions and outcomes data from around the country to create a platform where physicians and health systems have real-time access to clinical decision-making and outcomes data support in a way that allows them to more meaningfully participate in the shift to value-based care.

    Q: Can you share some of the hospitals/health systems and medical device companies FHW has partnered with in the U.K.? 

    TH: We have been fortunate to work in many countries and on multiple continents. In the U.K., we have worked with large [National Health Service] hospitals and trusts throughout the country. We also work with several of the leading device and implant companies across much of the E.U. Collectively, these companies make up about 50 percent of the device, implant and surgical robotics volume in the E.U.

    Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

    Featured Learning Opportunities

    Featured Webinars

    Featured Podcast

    Featured Whitepapers